Black Titan Corp

Análisis de la acción Black Titan Corp (BTTC)

$0.402

-0.011 (-2.83%)Al cierre

Loading chart…
High
0.410
Open
0.410
VWAP
0.40
Vol
114.02K
Mkt Cap
Low
0.400
Amount
46.08K
EV/EBITDA, TTM
0.00

Black Titan Corporation is a holding company that operates through its subsidiaries, Titan Pharmaceuticals Inc. (TTNP), and TalenTec Sdn Bhd (TalenTec). TTNP is a pharmaceutical company that was previously developing therapeutics utilizing the proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. ProNeura consists of a small, solid implant made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The resulting product is a solid matrix that is designed to be administered sub-dermally in a brief, outpatient procedure and is removed in a similar manner at the end of the treatment period. TalenTec is a provider of HCM software in Malaysia. It has introduced numerous human capital management (HCM) solutions to that market, such as Oracle PeopleSoft HCM, Oracle PeopleSoft Financials, Sunfish Workplaze HR, DayForce HCM, and MiHCM Cloud, through its holistic, integrated and reliable services.

AI analysis of Black Titan Corp (BTTC)

sell

Black Titan Corp is not a good buy right now due to its significant decline in performance and negative financial indicators. The stock price has dropped 76.02% year-to-date, and the RSI is at a very low 6.546, indicating extreme oversold conditions. Additionally, the company's gross margin has decreased to 26.76%, down from 36.90% in the previous year, highlighting deteriorating profitability. The main risk is the negative net margin of -262.14%, which suggests severe financial distress.

Métricas de valoración

The current forward P/E ratio for Black Titan Corp (BTTC) is 0.00, compared to its 5-year average forward P/E of 0.00.

Forward P/E

Strongly Undervalued
5Y Average P/E
0.00
Current P/E
0.00
Sobrevalorada
0.00
Infravalorada
0.00

Forward EV/EBITDA

Strongly Undervalued
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Sobrevalorada
0.00
Infravalorada
0.00

Forward P/S

Strongly Undervalued
5Y Average P/S
0.00
Current P/S
0.00
Sobrevalorada
0.00
Infravalorada
0.00

Cronología de eventos

2026-07-21 (ET)

09:30:00

Black Titan Announces Strategic Growth Initiatives to Expand Southeast Asia Market

2026-02-19 (ET)

10:40:00

Black Titan Corporation Signs Strategic MOU with PyratzLabs

2025-12-11 (ET)

09:40:00

Black Titan Releases Second Pillar of DAT+ Strategic Framework

08:50:00

Black Titan Introduces Digital Asset Strategic Framework DAT+

2025-11-12 (ET)

08:39:44

Black Titan names Lin as co-CEO

Noticias

BTTC FAQ — answered by Alphio AI

Black Titan Corporation is a holding company that operates through its subsidiaries, Titan Pharmaceuticals Inc. (TTNP), and TalenTec Sdn Bhd (TalenTec). TTNP is a pharmaceutical company that was previously developing therapeutics utilizing the proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. ProNeura consists of a small, solid implant made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The resulting product is a solid matrix that is designed to be administered sub-dermally in a brief, outpatient procedure and is removed in a similar manner at the end of the treatment period. TalenTec is a provider of HCM software in Malaysia. It has introduced numerous human capital management (HCM) solutions to that market, such as Oracle PeopleSoft HCM, Oracle PeopleSoft Financials, Sunfish Workplaze HR, DayForce HCM, and MiHCM Cloud, through its holistic, integrated and reliable services. It operates in the Financials sector.

Black Titan Corp is not a good buy right now due to its significant decline in performance and negative financial indicators. The stock price has dropped 76.02% year-to-date, and the RSI is at a very low 6.546, indicating extreme oversold conditions. Additionally, the company's gross margin has decreased to 26.76%, down from 36.90% in the previous year, highlighting deteriorating profitability. The main risk is the negative net margin of -262.14%, which suggests severe financial distress.

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empieza gratis